2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers
OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.
Related Articles
Northwell Cancer Institute Names Global Oncology Researcher Geraldine O’Sullivan Coyne, MD, PhD, to lead START Unit’s Early-Stage Clinical Trials
Northwell Cancer Institute appointed Geraldine O’Sullivan Coyne, MD, to The START Center for Cancer Research to bring trials to the community setting.
EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia
The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.
ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen
Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.
Dr Shah on Disease-Related Exacerbation With ICIs in Patients With Cancer and Preexisting NAIDs
Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.
Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders
A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.
Natural Language Processing Streamlines Clinical Encounter Note Collection in Indolent Systemic Mastocytosis
Natural language processing models could help streamline processes within clinical settings.
Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC
Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.
Transforming Colorectal Cancer Care: The Critical Role of Biomarker Testing in Early Detection and Disease Management
Sponsored Content by Pfizer, Inc.
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.
FDA Grants Fast Track Designation to TRE-515 Plus Radioligand Therapy in PSMA+ mCRPC
TRE-515 has received FDA fast track designation in combination with radioligand therapy for PSMA-positive mCRPC.